239 related articles for article (PubMed ID: 15858091)
1. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
3. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
[TBL] [Abstract][Full Text] [Related]
4. Low-dose thalidomide treatment for advanced hepatocellular carcinoma.
Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL
Oncology; 2003; 65(3):242-9. PubMed ID: 14657598
[TBL] [Abstract][Full Text] [Related]
5. Investigating the role of angiogenesis in systemic lupus erythematosus.
Liu J; Wang X; Yang X; Yan Q; Wang S; Han W
Lupus; 2015 May; 24(6):621-7. PubMed ID: 25359881
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD;
Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350
[TBL] [Abstract][Full Text] [Related]
8. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
[TBL] [Abstract][Full Text] [Related]
9. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
10. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
Sacco R; Faggioni L; Bargellini I; Ginanni B; Battaglia V; Romano A; Bertini M; Bresci G; Bartolozzi C
Dig Liver Dis; 2013 Sep; 45(9):776-81. PubMed ID: 23578581
[TBL] [Abstract][Full Text] [Related]
11. [Interest of color Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma].
Lassau N; Chawi I; Rouffiac V; Bidault S; Escudier B; Leclère J
Bull Cancer; 2004; 91(7-8):629-35. PubMed ID: 15381453
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
13. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
[TBL] [Abstract][Full Text] [Related]
14. Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experience.
Petralia G; Fazio N; Bonello L; D'Andrea G; Radice D; Bellomi M
J Comput Assist Tomogr; 2011; 35(2):195-201. PubMed ID: 21412089
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic activity of vitexicarpine in experimentally induced hepatocellular carcinoma: Impact on vascular endothelial growth factor pathway.
Hassoun SM; Abdel-Rahman N; Eladl EI; El-Shishtawy MM
Tumour Biol; 2017 Jun; 39(6):1010428317707376. PubMed ID: 28651490
[TBL] [Abstract][Full Text] [Related]
18. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide.
Patt YZ; Hassan MM; Lozano RD; Ellis LM; Peterson JA; Waugh KA
Am J Clin Oncol; 2000 Jun; 23(3):319-21. PubMed ID: 10857902
[TBL] [Abstract][Full Text] [Related]
19. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
Cipriani G; Mazzanti R
Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
[No Abstract] [Full Text] [Related]
20. Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study.
Nishida M; Koito K; Hirokawa N; Hori M; Satoh T; Hareyama M
Ultrasound Med Biol; 2009 Feb; 35(2):175-85. PubMed ID: 18845377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
